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Objectives: To evaluate the efficacy of gentamicin-loaded poly (lactide-co-glycolide) 50:50H (PLGA
50:50H) microspheres for the treatment of mice experimentally infected with Brucella abortus 2308.
Methods: The microspheres were dispersed in either 2% (w/v) poloxamer 188 saline solution, or de-
ionized water with the help of a cell homogenizer to break up particle aggregates, and were adminis-
tered intravenously or intraperitoneally to B. abortus-infected mice 7 days post-infection.
Results: Neither a single intravenous or intraperitoneal dose of 67mg of gentamicin per mouse, nor
three intraperitoneal doses of 100mg of gentamicin per mouse, reduced the Brucella infection in the
spleen compared with untreated mice 1 and 3 weeks post-treatment. Histological examination revealed
granulation and tissue reaction in the periphery of spleen and liver of animals given three doses of the
gentamicin-loaded microspheres.
Conclusions: The lack of therapeutic activity of the gentamicin-loaded microspheres might be related
to inappropriate microsphere size and aggregation, resulting also in a poor distribution of the micro-
spheres in the spleen. The results might provide an example of practical problems related to particle
size and aggregation for in vivo therapy with PLGA microspheres.
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Introduction
Brucellosis is a zoonosis of important socio-economic repercus-
sion, since apart from being a major animal health problem, it
constitutes a risk to human health. Brucella is a facultative intra-
cellular Gram-negative bacterium and its localization within ph-
agocytes makes treatment difficult.1 In vivo, Brucella is mainly
localized in cells and organs of the mononuclear phagocytic sys-
tem such as the macrophages of the spleen and the Kupffer cells
of the liver. Current therapy is based on a prolonged adminis-
tration of a tetracycline–aminoglycoside combination that often
leads to poor patient compliance, low therapeutic efficacy, fre-
quent relapses and serious side effects.2 As a consequence, there
is a recognized need for improvement of the actual treatment of
human brucellosis. Hence, the use of particulate carriers has
been proposed to target antibiotics to intracellular sites where
the bacteria are located. When targeting is combined with con-
trolled delivery of antibiotic drugs, the number of doses and
hence the toxicity of the drug may be decreased.
Gentamicin sulphate is an aminoglycoside with a wide spec-
trum of antibacterial activity, although nephrotoxicity restricts
the use of these compounds. As a cationic and freely water sol-
uble drug, it penetrates poorly into cells, constituting a drawback
for treating intracellular bacterial infections. Microspheres are
known to accumulate in organs of the monocyte-macrophage
system after parenteral administration. In addition, PLGA-micro-
spheres are biodegradable and tissue biocompatible. Micro-
spheres based on poly (lactide-co-glycolide) (PLGA) wherein
gentamicin is entrapped, have been prepared to target gentamicin
to the cells of the monocyte-macrophage system, reduce drug
toxicity and control its release over several days. We have pre-
viously shown that PLGA-microspheres loaded with gentamicin
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Table 1. Antibacterial effect of one or three doses of gentamicin (GEN), free or encapsulated into PLGA 50:50H microspheres, on Brucella abortus 2308-infected mice (control
groups received saline or water, or placebo microspheres)
Mean log10 cfu/spleen ± SD
a Mean weight (g)/spleen
Formulationb,c
No. of
doses
Dose (mg of
GEN/mouse) day 0d 1 weekd 3 weeksd day 0d 1 weekd 3 weeksd
Saline (iv)b 1 0 6.34 ± 0.60 (6) 5.53 ± 0.22 (6) 6.01 ± 0.23 (6) 0.30 ± 0.09 0.53 ± 0.11 0.37 ± 0.07
GEN (iv)b 1 67 – 5.69 ± 0.36 (6) 6.33 ± 0.30 (6) – 0.41 ± 0.22 0.39 ± 0.09
GEN-loaded microspheres (iv)b 1 67 – 5.48 ± 0.69 (6) 4.82 ± 2.01 (6) – 0.36 ± 0.17 0.27 ± 0.14
Placebo microspheres (iv)b 1 0 – 5.86 ± 0.46 (6) 6.08 ± 0.19 (6) – 0.43 ± 0.09 0.41 ± 0.11
GEN-loaded microspheres (ip)b 1 67 – 4.91 ± 1.56 (5) NDe – 0.43 ± 0.20 NDe
Placebo microspheres (ip)b 1 0 – 5.64 ± 0.19 (5) NDe – 0.29 ± 0.12 NDe
Water (ip)c 3 0 6.73 ± 0.56 (6) 6.08 ± 0.45 (6) 6.39 ± 0.58 (6) 0.37 ± 0.10 0.43 ± 0.07 0.55 ± 0.19
GEN (ip)c 3 100 – 6.14 ± 0.28 (6) 6.82 ± 0.23 (6) – 0.54 ± 0.21 0.70 ± 0.13
GEN-loaded microspheres (ip)c 3 100 – 6.20 ± 0.32 (6) 6.22 ± 0.37 (6) – 0.56 ± 0.21 0.51 ± 0.25
Placebo microspheres (ip)c 3 0 – 6.14 ± 0.26 (6) 6.78 ± 0.08 (6) – 0.51 ± 0.18 0.65 ± 0.17
aFive or six mice per group were used.
bThe different formulations were prepared in a 2% (w/v) poloxamer 188 in saline and administered intravenously (iv) or intraperitoneally (ip) in a single dose (0.2 mL/mouse). Microsphere dispersion was
helped by brief sonication. The formulations were injected 1 week after the infection of the mice with Brucella abortus, 0.87106 cfu/mouse (in stationary growth phase).
cThe different formulations were prepared in sterile deionized water helped by 1 min of sonication and 2 min of homogenization by pounding in a glass cell homogenizer and three doses were injected
intraperitoneally (ip) during three consecutive days (0.5 mL/dose). The formulations were injected 1 week after the infection of the mice with Brucella abortus, 1.8106 cfu/mouse (in exponential growth
phase). The inoculum was prepared by first seeding the Brucella onto TSB for exponential bacteria growth and diluting the suspension in saline solution to the adequate concentration.
dTime post-treatment.
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are readily phagocytosed by monocytes, induce monocyte acti-
vation,3 and transport the drug into cells, thereby decreasing
Brucella abortus infection in J774 cultured cells.4
Here we studied the efficacy of PLGA 50:50H-microspheres
containing gentamicin in mice experimentally infected with Bru-
cella abortus 2308. Histological studies were also carried out to
give insights of microsphere biodistribution and tissue response
to these carriers.
Materials and methods
Preparation and characterization of the microspheres
Gentamicin-loaded PLGA 50:50H microspheres were prepared by
spray-drying as described elsewhere.5 Briefly, 100 mg of gentamicin
was dissolved in 1 mL of phosphate buffer (67 mM, pH 7.4) and dis-
persed in a 5% (w/w) polymer solution in ethyl formate by ultraso-
nication. The water-in-oil emulsion formed was spray-dried (Bu¨chi
190, Flawil, Switzerland) and the resulting microspheres collected,
washed and dried under vacuum. The final product was stored at
48C. Placebo microspheres were produced similarly.
Microsphere size distribution was determined by laser light scat-
tering (Mastersizer X, Malvern, UK) and morphology was examined
by scanning electron microscopy (Zeiss DSM 940A).
Measurement of gentamicin content in the microspheres was
achieved by dissolving the microspheres in dichloromethane and
collecting the undissolved gentamicin on cellulose acetate filters.
The gentamicin was eluted from the dried filters with water and
assayed photometrically after derivation with o-phthalaldehyde.5
In vivo experimental Brucella abortus infection and
treatment with microencapsulated gentamicin
Animals: Female Swiss-Webster mice (20 ±1 g) were used under
Protocol 039/00 (Ethics Committee for Animal Experimentation,
CEEA, University of Navarra, Spain, 2000).
Brucella strain: Brucella abortus 2308 isolates from spleens of
infected mice and maintained on skimmed milk at 858C were
used. For infection of the mice, the brucellae were thawed, seeded
onto trypticase soy agar (TSA) plates and incubated for 2–3 days at
378C. Isolated colonies were transferred into 5 mL of trypticase soy
broth and incubated for 24 h at 378C under shaking (exponential
growth phase). The bacterial suspension was then diluted in saline
solution to the adequate bacteria concentration to infect the animals.
In some experiments, the bacteria were thawed and, immediately
before injection, the suspension was diluted in saline (stationary
growth phase).
Infection of mice with Brucella abortus 2308 and treatment with
microencapsulated gentamicin: Mice were infected intraperitoneally
with  1106 cfu per mouse (300mL). On day 7 after infection, the
mice received free gentamicin, gentamicin-loaded microspheres,
placebo microspheres or a blank solution. The gentamicin-treated
animals received a single dose of 67mg of gentamicin per mouse
(0.2 mL) administered intravenously or intraperitoneally, or three
doses of 100mg of gentamicin/dose/mouse (0.5 mL) administered
intraperitoneally on three consecutive days. Poloxamer 188 (2%,
w/v) was used in the 1-dose treatments to facilitate the dispersion of
the microspheres and as control in the blank and free gentamicin
solutions; water was used in the 3-dose treatments and microspheres
were dispersed with the aid of a cell homogenizer. The efficacy of
the treatments was determined by counting the number of viable
Brucella in spleen homogenates 1 and 3 weeks post-treatment after
diluting and seeding onto TSA plates.
Histological examination
Healthy mice were injected intraperitoneally with three doses of
gentamicin-loaded microspheres containing 100mg of gentamicin/
dose/mouse on three consecutive days. The spleen and liver were
removed aseptically 24 h after the treatment and the organs were
prepared for histological examination.
Results and discussion
Efficacy of gentamicin treatment on Brucella abortus-infected
mice
The intravenous route of administration limited the amount of
microspheres injected (4.5 mg of microspheres) and, thus, the
gentamicin dose to only 67mg. The mean diameters of the
microspheres ( 3mm) should have been suitable for intravenous
administration, however, dispersibility, concentration, homogen-
eity and stability in the dispersed state also need to be adequate.
Typically, PLGA 50:50H particles exhibited a strong tendency
to aggregate, especially when loaded with gentamicin.5 Although
rarely reported, dispersibility of PLA/PLGA microspheres is
influenced by many factors such as size, shape, drug/polymer
charge, pH and viscosity of the vehicle.6 Poloxamer 188 was
used to improve the dispersion characteristics; moreover, a ben-
eficial effect of the poloxamer on the antibiotic activity of the
gentamicin-loaded microspheres in vitro was previously
observed.4 After 1 or 3 weeks, none of the 1-dose treatments,
intravenously or intraperitoneally administered, had a significant
effect on the bacterial counts in the spleen compared with the
saline control group (P > 0.05, Student’s t-test) (Table 1). How-
ever, the mice treated with the encapsulated gentamicin showed
high SD values due to a few individual mice exhibiting low bac-
teria numbers per spleen. This correlated with a slightly lower
weight of the spleens of animals treated with gentamicin-loaded
microspheres at 3 weeks post-treatment compared with the saline
group, but the effect was not statistically significant (P > 0.05,
Student’s t-test). Despite the good dispersion state of the micro-
spheres, increasing the number of doses or the microsphere
concentration administered intravenously led to respiratory pro-
blems for the animals, which became very weak and lethargic or
died from pulmonary embolism.
When the antibiotic dose was increased by treating the
infected mice with three doses of 100mg of gentamicin, given
intraperitoneally in solution or encapsulated in the PLGA
50:50H microspheres, no effect on the number of viable bacteria
in the spleen or on spleen weights was observed (Table 1).
Besides a possible sub-therapeutic dose of gentamicin, poor
accumulation of the microspheres in the spleen, considered as
the target organ, may have been responsible for the results.
Accumulation of particles in the spleen is generally lower than
in the liver, probably also due to the respective weights of these
organs. Hence, we may suggest that the amount of PLGA micro-
spheres reaching the spleen in our model could have been insuf-
ficient to produce a significant decrease in the bacterial counts.
Histological examinations
Structures resembling abscesses were observed macroscopically
in livers and spleens of healthy mice 24 h after they were given
three doses of the gentamicin-loaded microspheres intraperiton-
eally. Histological examination under light microscope revealed
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inflammation of the spleen and liver capsule with localized pre-
sence of polymorphonuclear leucocytes (Figure 1). Granulation
tissue was found in the periphery of these organs, with typical
tissue necrosis, new blood capillary formation, fibroblast pro-
liferation and the accumulation of high numbers of leucocytes.
Empty vacuoles were observed in the interior of monocyte-
macrophage cells from the periphery granulation tissue of both
organs (Figure 1). Similarly, Schmidt et al.7 observed empty
vacuoles in macrophages of tissue surrounding PLGA/PLA
implants and associated them with reabsorbed detached polymer.
These cellular and tissue host reactions may indicate that the
administered microspheres reached the spleen and liver. The
peripheral location of the response may also indicate that the
microspheres reached only the periphery of the organ because
they may have been trapped at the capillary level irrigating the
spleen. In agreement with this suggestion, Jani et al.8 observed
the presence and alignment of large polystyrene particles in the
trabeculae of the spleen but not small ones (<1mm), suggesting
the fenestrations between trabeculae and reticular spaces may
have trapped particles of micrometre size but not smaller. Fur-
thermore, intraperitoneally-injected PLA microspheres have
been shown to spread over the whole peritoneal cavity and to
distribute in the serosal membranes of the mesentery, internal
organs or the peritoneum.9 Besides, important particle accumu-
lation in lungs and lymph nodes draining the peritoneal cavity
should be expected depending on characteristics of the par-
ticles.10 In view of this, microsphere distribution to various
organs (liver, spleen, lung, lymph nodes, peritoneal cavity),
along with a poor intrasplenic distribution, possibly due to
entrapment in the peripheral capillary network, could explain the
lack of efficacy of the systems studied here for reducing Bru-
cella abortus counts in the spleen of mice. Nevertheless, evalu-
ation of spleen counts at different or longer times post-treatment
may have produced a different result. It may be speculated that
particle aggregates could gradually decrease in size upon degra-
dation and deglomeration. Therefore, a redistribution and further
cellular uptake of particles of appropriate size might be feasible,
which may finally yield antibacterial effects.
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